RxDoctor Payments Data

Parag Patel, MD

Cardiovascular Disease · Bridgewater, NJNPI 1598738858

Payments from drug & device makers

$18,892in general payments, 2019–2025

Across 492 payments — averaging $38.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Philips North America LLC$3K
  • Boston Scientific$2K
  • Cardiovascular Systems Inc.$745
  • Edwards Lifesciences$726
  • Endologix LLC$698
  • plus $7K from 45 others

What the payments were for

  • Travel & lodging$4,01121%
  • Food & beverage$14,83779%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,892 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$367,929
Medicare patients
1,279
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$249,677
XareltoRivaroxaban43$61,613
EntrestoSacubitril/Valsartan17$31,976
BrilintaTicagrelor31$28,135
FarxigaDapagliflozin Propanediol23$24,829
JardianceEmpagliflozin22$24,249
Repatha SureclickEvolocumab21$18,799
TenorminAtenolol12$10,400
Metoprolol Succinate593$9,616
Atorvastatin Calcium702$7,320
ClopidogrelClopidogrel Bisulfate370$5,898
Ezetimibe67$3,842
Losartan Potassium317$3,084
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid12$3,031
Ezetimibe-SimvastatinEzetimibe/Simvastatin13$2,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$249,677197 claims
Johnson & JohnsonXarelto$165$61,61343 claims
AstraZenecaBrilinta, Farxiga$688$52,96454 claims
NovartisEntresto$453$31,97617 claims
Boehringer IngelheimJardiance$485$24,24922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →